Craft

Deciphera Pharmaceuticals

Stock Price

$25.4

2024-05-03

Market Capitalization

$2.1 B

2024-05-03

Revenue

$163.4 M

FY, 2023

Deciphera Pharmaceuticals Summary

Company Summary

Overview
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. It utilizes its drug discovery platform and designs kinase inhibitors. The pipeline includes ripretinib, vimseltinib, rebastinib, and DCC-3116.
Type
Public
Status
Active
Founded
2003
HQ
Waltham, MA, US | view all locations
Website
https://www.deciphera.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Steven L. Hoerter

    Steven L. Hoerter, President, Chief Executive Officer

  • Daniel L. Flynn

    Daniel L. Flynn, Executive Vice President, Chief Scientific Officer and Founder

  • Jeff Held

    Jeff Held, Senior Vice President, General Counsel

  • Caroline Chevalier

    Caroline Chevalier, Vice President, Human Resources

Operating MetricsView all

Patents (US)

11

Aug, 2017

Patents (Foreign)

47

Aug, 2017

Patent Applications

49

Aug, 2017

LocationsView all

2 locations detected

  • Waltham, MA HQ

    United States

    200 Smith St

  • Lawrence, KS

    United States

    643 Massachusetts St, Suite 200

Deciphera Pharmaceuticals Financials

Summary Financials

Revenue (FY, 2023)
$163.4M
Gross profit (FY, 2023)
$159.6M
Net income (FY, 2023)
($194.9M)
Cash (Q1, 2024)
$91.2M
EBIT (FY, 2023)
($211.0M)
Enterprise value
$2.0B

Footer menu